WCLC 2025 - Posters & ePosters-EP.12.12 Efficacy of Lazertinib in Treatment-Naive Patients for EGFR Mutated Non-Small Cell Lung Cancer With Brain Metastases

EP.12.12 Efficacy of Lazertinib in Treatment-Naive Patients for EGFR Mutated Non-Small Cell Lung Cancer With Brain Metastases

Back to course

Pdf Summary

This single-center, open-label phase II study evaluated Lazertinib, a tyrosine kinase inhibitor (TKI), as a first-line treatment for treatment-naive patients with EGFR-mutated non-small cell lung cancer (NSCLC) who have brain metastases, including those exhibiting neurologic symptoms. NSCLC with EGFR mutations is known for a high incidence of brain metastases. While combining EGFR-TKIs with local therapies is standard, data on symptomatic brain metastases remains limited.<br /><br />Seventy-five patients (38 symptomatic, 37 asymptomatic) participated, with a median follow-up of 13.6 months. Baseline characteristics showed no significant differences in age or mutation types between groups, although symptomatic patients had larger brain lesions and more frequent hypertension. Initial treatment mostly involved Lazertinib monotherapy, with some receiving Lazertinib combined with surgery, Gamma Knife radiosurgery, or whole-brain radiotherapy.<br /><br />Progression-free survival (PFS) analysis using Kaplan-Meier curves revealed that Lazertinib conferred favorable PFS regardless of the presence of initial neurologic symptoms. Quality of life assessments, via QLQ-C30 symptom scores, demonstrated symptom improvement in both symptomatic and asymptomatic groups after treatment. A case example showed marked regression of a 1.3-cm brain metastasis on MRI after three months of Lazertinib monotherapy.<br /><br />Overall, Lazertinib was effective in controlling brain metastases and improving cancer-related symptoms in EGFR-mutated NSCLC patients, irrespective of initial neurologic status. This suggests Lazertinib monotherapy could be a potent first-line therapy option. The study was funded by Yuhan Corporation and conducted by the Asan Medical Center in South Korea.

Asset Subtitle

Hyun Seok Kwak

Meta Tag

Speaker Hyun Seok Kwak

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

Lazertinib

EGFR-mutated non-small cell lung cancer

brain metastases

tyrosine kinase inhibitor

first-line treatment

symptomatic brain metastases

progression-free survival

quality of life

monotherapy

Asan Medical Center